Recently, certain lots of heparin have been associated with an acute, rapid onset of serious side effects indicative of an allergic-type reaction. To identify potential causes for this sudden rise in side effects, we examined lots of heparin that correlated with adverse events using orthogonal high-resolution analytical techniques. Through detailed structural analysis, the contaminant was found to contain a disaccharide repeat unit of glucuronic acid linked β1→3 to a β-N-acetylgalactosamine. The disaccharide unit has an unusual sulfation pattern and is sulfated at the 2-O and 3-O positions of the glucuronic acid as well as at the 4-O and 6-O positions of the galactosamine. Given the nature of this contaminant, traditional screening tests cannot differentiate between affected and unaffected lots. Our analysis suggests effective screening methods that can be used to determine whether or not heparin lots contain the contaminant reported here.
Heparin, a complex glycosaminoglycan polysaccharide, is widely used as an anticoagulant in a number of settings, including kidney dialysis and acute coronary syndromes [1] [2] [3] . The most serious adverse event associated with heparin, aside from a potential bleeding risk, is thrombocytopenia. Recently there has been a marked increase in serious adverse events associated with heparin therapy, with hundreds of individuals affected [4] [5] [6] [7] . Although heparin therapy is generally well tolerated, recently patients presented-within several minutes after intravenous infusion of unfractionated heparin-with angioedema, hypotension, swelling of the larynx and related symptoms, which in some cases ended in death. Because heparin is a drug commonly used in the clinic, occurrence of these adverse events resulted in a crisis in the United States. Germany and other nations in the European Union have observed similar phenomena, turning this health problem into an international issue 4, 5 . The rapid onset of these symptoms suggests an anaphylactic response, but the exact etiology is currently unknown. Given the clinical history of heparin, this spike in adverse events suggests the potential contamination of heparin. However, standard testing of heparin lots for typical biological contaminants, including protein, lipids and DNA (which, if present, may elicit such side effects), indicated that there is no difference in these regards between lots that elicit adverse events and those that do not 4 . Despite extensive analysis, no obvious differences were found with respect to other potential contaminants, including lead, dioxins and other molecular entities 8 . Definitive identification of how these heparin lots differ from the clinically approved heparin thus becomes imperative 9 .
To understand the structure or structures of the contaminant(s) present within specific lots of heparin, we sought to identify these contaminants. This exercise required the use of multiple orthogonal techniques, including multidimensional NMR, to overcome the challenges inherent in the analysis of complex polysaccharides, including heparin, which in and of itself comprises a complex mixture of glycosaminoglycan chains. In doing so, we were able to determine definitively the structure of the contaminant, isolate it and confirm its structural identity by comparison to a chemically synthesized standard.
RESULTS

NMR shows unusual N-acetyl signals not seen in heparin
For this study, we examined lots that were associated with adverse clinical reactions (designated S1-S6) as well as four control lots of heparin not associated with adverse events (designated C1-C4). Initial analysis of S1-S6 by one-dimensional NMR indicated that all of these samples produced an unusual series of N-acetyl signals (Fig. 1a, Supplementary Figs. 1 and 2 online) . For example, particularly evident in the proton spectrum of S1 is the signal at 2.16 p.p.m. corresponding to an N-acetyl group different from that of heparin (2.04 p.p.m.). This N-acetyl signal is also distinct from that of dermatan sulfate, a known impurity in heparin samples (2.08 p.p.m) 10 . To complement and extend the proton analysis, carbon (100 MHz) NMR spectroscopy was performed. Comparison of the carbon spectra of S1 and C1 indicates the presence of several additional signals not normally associated with heparin structural signatures (Fig. 1b) To further identify the number and type of any major contaminants, we collected multidimensional heteronuclear single quantum coherence (HSQC) spectra on S1 and C1 to separate the observed signals in two dimensions-the carbon and proton signals. Ten major signals observed in sample S1 were not seen in C1. These same signals were observed in samples S2-S6 but not in samples C2-C4 ( Supplementary Figs. 3 and 4 online). In addition, these results and those from other two-dimensional experiments, including total correlation spectroscopy (TOCSY), correlation spectroscopy (COSY) and rotating-frame nuclear Overhauser effect spectroscopy (ROSEY), were also consistent with the basic findings outlined above, namely that the principal contaminant consists of a polymeric repeat of N-acetylgalactosamine linked to glucuronic acid exclusively through beta linkages.
Identification of an impurity and a contaminant in heparin
Much of the analysis outlined above focused on sample S1, as it possessed signals in the N-acetyl region at 2.04 p.p.m (arising from heparin) and at 2.16 (arising from the unknown contaminant). In addition to this unusual signal at ~2.16 p.p.m, some samples (S2-S6 and C2-C4) possessed an additional N-acetyl peak ( Supplementary  Fig. 5b online) , which had a chemical shift of 2.08 p.p.m, indicating the presence of another species that is distinct from the contaminant. Given the observed chemical shifts, this species is most likely dermatan sulfate, a known natural impurity of heparin 10, 11 . To confirm the identity of this species, we performed a two-dimensional (2D) 1 H-13 C HSQC experiment on C2 (Supplementary Fig. 5d ) and compared the results to those obtained on C1, a sample that did not show this additional signal. The chemical shifts observed in C2 but not in C1 are similar to those reported in the literature 10 , and this observation suggests that the additional peaks in the HSQC of C2 can be assigned to dermatan sulfate. This assignment was confirmed by comparison to 1 H and HSQC data obtained on a standard of dermatan sulfate (Supplementary Fig. 5a,c) . Through an analysis similar to that completed on sample C2, we confirmed the presence of dermatan sulfate in those samples presenting a proton NMR signal at 2.08 p.p.m. Therefore, samples S2-S6, but not sample S1, contained both dermatan sulfate (an impurity typically found in heparin) and the unusual contaminant.
Finally, to confirm the findings from the NMR analysis of the samples, we conducted enzymatic digestion of S1-S6 and C1-C4 with either a combination of heparinases or heparinases plus ∆4,5 glycuronidase and 2-O sulfatase followed by separation and analysis by high-performance liquid chromatography (HPLC). Digestion with the heparinases reduces heparin to its component di-, tri-and tetrasaccharides and imparts a ∆4,5 bond that can be monitored at 232 nm; completed in conjunction with treatment with glycuronidase and sulfatase, this digest permits the identification of minor heparin species, including those disaccharides containing a modified galacturonic acid 12, 13 . Thus, concomitant use of a matrix of enzymes, especially in conjunction with liquid chromatography-tandem mass spectrometry analysis, allows for the complete separation, identification and quantification of heparin components in the mixture 14 . We find that the total areas under the curve, calculated by integration of all heparin di-, tri-and tetrasaccharides observed in the HPLC and summation of the resulting areas, of digested S1-S6 are substantially less than those of the control samples, indicating that the major contaminant is not substantially digested by the heparinases (Table  1) . Furthermore, the difference in the area under the curve is correlated with the amount of contaminant present within the sample; samples with larger amounts of contaminant (as measured by proton NMR) had a lower area under the curve as measured by HPLC. Finally, the relative quantities of the individual heparin components are similar between the controls and suspect samples, with only minor differences.
To identify the unknown compound present in the contaminated heparin samples, we attempted to isolate the contaminant using a variety of methods. Given the overall properties of the contaminant, elucidated through NMR, capillary electrophoresis and HPLC analysis, we reasoned that this material could be differentially precipitated upon addition of an organic solvent. Partial purification of the contaminant was indeed achieved through the addition of increasing amounts of ethanol to an aqueous solution of S1. Similarly, because the contaminant contains N-acetylhexosamine (and not N-sulfohexosamine), it was also purified by degradation of heparin by nitrous acid and isolation of the remaining components.
Isolation of the contaminant allowed definitive identification
After isolation, the proton spectrum of the isolated contaminant reveals a residual heparin content of ~10-30% (depending on the isolation method used) as determined by one-dimensional NMR (data not shown). We carried out additional, detailed NMR studies on this isolated sample. To facilitate an understanding of the experiments and their interpretation, the disaccharide repeat structures of heparin, chondroitin sulfate, dermatan sulfate and heparin, together with positional nomenclature, are presented in Figure 2 . In the carbon spectrum, at neutral pH values, one apparent signal arises at 177.6 p.p.m, characteristic of carbonyl groups. Acidification of a solution of the product from pH 6.5 to pH 4 ( Fig. 3a) reveals two distinct carbonyl signals consistent with the carbonyl group of an N-acetyl function and the protonated form of carboxylic acid, respectively. Similar shifts were not observed for any other signals except C-5 of uronic acid (U5), for which this carbon's chemical shift is sensitive to the ionization state of the carboxylic acid as well as the identity of the counterion present (Fig. 3b) . To further characterize the isolated sample, we used homonuclear (COSY and TOCSY, data not shown) and heteronuclear (HSQC, HSQC-TOCSY and heteronuclear multiple bond correlation (HMBC)) 2D-NMR spectroscopy (Fig. 3c,d ). These analyses indicated the presence of two types of residues. Chemical shift patterns were in agreement with one type of monosaccharide being a 4,6-O-sulfo-N-acetylgalactosamine and the other being a 2,3-O-sulfoglucuronic acid. In addition to confirming the assignments of the sugar moieties, the HMBC spectrum demonstrated the correlation across the glycosidic linkages, indicating the presence of a β-1,4 linkage between galactosamine and glucuronic acid and a β-1,3 linkage between the glucuronic acid and the galactosamine. Confirmatory evidence of this structure was provided by the long-range correlations of H1 of the galactosamine and H5 of glucuronic acid with two different carbonyl groups (177.5 and 177.8 p.p.m) owing to the N-acetyl of galactosamine and the carboxylic group of glucuronic acid.
Synthetic oversulfated chondroitin matches contaminant
The identification of the contaminant as an oversulfated chondroitin sulfate containing a tetrasulfated disaccharide unit consisting of glucuronic acid linked to N-acetylgalactosamine was surprising, as this is an unusual structure. To ensure the accuracy of this assignment, we prepared a standard by oversulfation of chondroitin sulfate using well-established chemistry. We analyzed this A R T I C L E S standard by 2D NMR and carefully compared the HSQC spectra to both the literature 15 and the HSQC spectrum obtained for the isolated contaminant. Comparison of the HSQC spectrum of the synthesized standard with that of the isolated contaminant (Fig. 4) confirmed that the major contaminant consists of per-O-sulfated chondroitin sulfate, with all of the hydroxyl groups of both the uronic acid and galactosamine residues bearing sulfate substituents.
Furthermore, the proton chemical shifts of the contaminant ( Table 2 ) are in agreement with those assigned to fully sulfated chondroitin (degree of sulfation = 4) 15 . In addition, mass spectrometry completed after enzymatic digestion of a chemically desulfated 16 version of the contaminant was consistent with the proposed structure (Fig. 5) . The final derived structure of the major contaminant present in heparin is shown in Figure 2a , with R 1 , R 2 , R 3 and R 4 all sulfated.
DISCUSSION
Several factors required the use of multiple approaches to ensure an accurate structural determination of the oversulfated chondroitin contaminant. First, heparin is a chemically complex polydisperse mixture of saccharides, making careful interpretation of results necessary to avoid misinterpretation. Detailed analysis is especially important when addressing the multiple isomeric possibilities within the chains of a complex mixture, and it necessitates the use of orthogonal techniques, including an enzyme matrix and multidimensional NMR. Second, oversulfated materials, such as the chondroitins, are resistant to enzymatic digestion techniques and copurify with heparin, rendering their isolation challenging 15, 17 .
These complexities manifest themselves in a number of ways: for example, structurally distinct species may have overlapping signals and properties, thereby 'masking' them within a single analysis. A nonintegrated approach can therefore potentially lead to false conclusions, especially when attempting to differentiate between heparin, dermatan sulfate and oversulfated chondroitin sulfate in any given sample. In this study, we present a set of experimental techniques that discriminate between dermatan sulfate (a known impurity of heparin) and oversulfated chondroitin sulfate.
The structure of the contaminant, which contains a tetrasulfated disaccharide repeat, is highly unusual. First, the presence of a 3-Osulfated glucuronic acid is rare, only observed in specific contexts within certain organisms 18 . In addition, a tetrasulfated disaccharide repeat unit has not been isolated to date from animal tissues. Consequently, it is highly unlikely that the contaminant reported here is produced naturally. Finally, chemically synthesized tetrasulfated disaccharide repeat units of chondroitin sulfate are known to exhibit a high degree of anti-factor IIa activity 15 , which could explain how contaminated heparin would pass an activity screen, such as a whole-blood coagulation test. Further investigation is warranted to understand how this contaminant was introduced.
With respect to the potential biological ramifications of this finding, it is possible that the presence of an oversulfated chondroitin sulfate within heparin preparations can provoke increased side effects. In the case of chondroitins, chondroitin sulfates A and C are expressed by human cells and are generally nonimmunogenic. Highly sulfated polysaccharides, however, such as oversulfated chondroitins, have been shown to be potent mediators of the immune response [19] [20] [21] [22] . Indeed, complications associated with administration of highly sulfated chondroitins have been observed in humans. Arteparon, an oversulfated chondroitin that is structurally identical to the contaminant 23 (Fig. 2) , injected intramuscularly in humans 24 , was marketed for the treatment of degenerative joint disease in Europe. It was demonstrated that this product can induce an allergic-type response 25 . Because of patient deaths, most likely due to thromboembolic complications, the product was rapidly withdrawn from the European market 26 . The structural determination of the contaminant described here enables further investigation into the biological roles and potential pharmacological effects of oversulfated chondroitins, present within heparin preparations, in the recently reported adverse events. Taken together, our orthogonal analytical experiments provide strong support for the structure we have assigned to the contaminant. This study also provides a set of screening methods that could be used to monitor the heparin supply and ensure the absence of oversulfated chondroitin sulfate contamination. For example, using the structural information presented here, it is now possible to (i) design reference standards that ensure accuracy, quantification and specificity of analysis for a given analytical method and (ii) devise an experimental protocol to clearly define the nature and extent, if any, of contamination in a given lot of heparin. Finally, the ramifications of these findings extend beyond scientific considerations and include clinical and health policy issues.
METHODS
Materials.
Chondroitin sulfate type A from whale cartilage, pyridine-sulfur trioxide complex, tributylamine, dry N,N-dimethylformamide, pyridine, methanol, dimethylsulfoxide, NaNO 2 , NaBH 4 , 2,2-dimethyl-2-silapentane-5-sulfonate sodium salt and sodium trimethylsilylpropionate were purchased from SigmaAldrich. 96%) . Before spectrum acquisition, samples were sonicated for 60 s to remove air bubbles. Spectra were obtained at 303 K or 308 K using a 600-MHz Varian VNMRS spectrometer or a 600-MHz Bruker Avance 600 spectrometer, both equipped with a 5-mm triple-resonance inverse cryoprobe. Monodimensional 1 H spectra were obtained with presaturation of residual HOD, for 32-128 scans. DQF-COSY and 2D-TOCSY spectra were acquired using 32 scans per series of 2,048 × 512 data points. HSQC and HSQC-TOCSY spectra were recorded with carbon decoupling during acquisition with 320 increments for 12-64 scans. The polarization transfer delay was set with a 1 J C-H coupling value of 155 Hz. HMBC spectrum was recorded with 320 increments of 64 scans for each, without carbon decoupling and with twofold low-pass Jfilter to suppress one-bond correlations 27 . The delay for evolution of long-range couplings was set with a J lr of 8 Hz. Samples for 13 C-NMR analysis were dissolved in D 2 O (99.9%) at 40 mg/ml and analysis was performed at 303 K with a 400-MHz Bruker spectrometer equipped with a multinuclear probe.
Composition analysis by ion-pair RPHPLC. Samples were constituted in capillary electrophoresis-grade water and digested under two different conditions. The first digest used an enzyme cocktail of heparinases I (500 mIU), II (400 mIU) and III (500 mIU) at 30 °C, for 16 h. A portion of this digest was further treated with 2-O-sulfatase (1,000 mIU) and ∆4,5-glycuronidase (2,000 mIU) for 6 h at 30 °C to obtain the second digest. Each digest was passed through a Ni 2+ spin column (Qiagen) and analyzed by ion-pair RPHPLC similar to as previously described 14 . Elution was monitored by UV detection at 232 nm.
Isolation of major contaminant. Absolute ethanol was added to sample S1 (300 mg), dissolved in 1.5 ml of water until a white precipitate appeared (ethanol 23%, vol/vol). Precipitated material was separated by centrifugation for 5 min at 5,000 r.p.m. (~4,000g) on a Labofuge 200 (Heraeus). In addition to the above, sample S1 was treated with nitrous acid 28 . A solution of the sample (500 mg) was dissolved in 20 ml of H 2 O and cooled at 4 °C. Also at 4 °C, 140 mg of NaNO 2 dissolved in 1 ml of water was added to the sample and the pH was adjusted to 1.7 with 0.1 M HCl. The solution was stirred at 4 °C for 20 min; an additional 100 mg NaNO 2 was added and the solution stirred for another 20 min. The solution pH was then adjusted to 7 with NaOH and the resulting reaction was brought to room temperature. Solid NaBH 4 (200 mg) was added in several portions with stirring. After 2 h, the pH was adjusted to 4 with 0.1 M HCl and the solution was neutralized with 0.1 M NaOH. The product, obtained by precipitation with four volumes of methanol, was recovered by centrifugation, dissolved in water and freeze-dried.
Chemical sulfonation of chondroitin sulfate. Fully sulfated chondroitin sulfate was prepared from chondroitin sulfate, as described 15 . Chondroitin sulfate (108 mg) was converted into its tributylamine salt and dissolved in dry N,N-dimethylformamide (1 ml). After addition of 159 mg of pyridine-sulfur trioxide complex, the solution was heated for 1 h at 40 °C . The reaction was interrupted by addition of 2 ml of water and the product was precipitated at 4 °C by addition of 35 ml of an ethanol solution saturated with sodium acetate. The product recovered by centrifugation was dissolved in water, dialyzed at room temperature and recovered by freeze-drying.
Note: Supplementary information is available on the Nature Biotechnology website.
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